---
title: "Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284340853.md"
description: "On April 28, 2026, in Hong Kong, Akeso, Inc.revealed that ivonescimab, their groundbreaking PD-1/VEGF bispecific antibody, has obtained significant enhancements and advancements in various treatment settings. The company's innovative drug has received widespread recognition and improvements for both initial and subsequent treatment stages."
datetime: "2026-04-28T08:10:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284340853.md)
  - [en](https://longbridge.com/en/news/284340853.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284340853.md)
---

# Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline

On April 28, 2026, in Hong Kong, Akeso, Inc. (9926.HK) revealed that ivonescimab, their groundbreaking PD-1/VEGF bispecific antibody, has obtained significant enhancements and advancements in various treatment settings. The company's innovative drug has received widespread recognition and improvements for both initial and subsequent treatment stages.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Bachem Annual General Meeting 2026 | BCHMY Stock News](https://longbridge.com/en/news/284610952.md)
- [04:07 ETIvonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline](https://longbridge.com/en/news/284338444.md)
- [Alibaba Group Will Announce March Quarter 2026 and Full Fiscal Year 2026 Results on May 13, 2026 | BABA Stock News](https://longbridge.com/en/news/284532744.md)
- [Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach | TLX Stock News](https://longbridge.com/en/news/284280065.md)
- [SanLuca and Sutter Health Partner to Integrate Behavioral Health in Hypertension Care](https://longbridge.com/en/news/284808060.md)